Business Context and Reporting Period
This Form 8-K, dated April 5, 2023, reports on Zura Bio Limited (Zura), a Cayman Islands company. The filing serves to provide the audited consolidated financial statements of Zura following its business combination with JATT Acquisition Corp, which was consummated on March 20, 2023. The financial data covers the period from Zura's inception on January 18, 2022, through December 31, 2022.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references Exhibit 99.1, which contains the audited consolidated financial statements for the period ended December 31, 2022, but the figures themselves are not included in the body of this report.
Material Changes
The primary material event reported is the completion of the business combination between Zura Bio Limited and JATT Acquisition Corp on March 20, 2023. This transaction resulted in Zura becoming a publicly traded entity on The Nasdaq Stock Market under the symbols "ZURA" (Class A Ordinary Shares) and "ZURAW" (Warrants).
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, or specific risk factors. It is a procedural filing intended to satisfy the requirement to disclose the financial statements of the business acquired in the merger. The company is identified as an emerging growth company.
Investor Verification Checklist
- Review Exhibit 99.1 for the actual audited financial figures for the period ended December 31, 2022.
- Verify the terms of the business combination with JATT Acquisition Corp consummated on March 20, 2023.
- Confirm the trading status and warrant exercise price ($11.50) for securities listed on The Nasdaq Stock Market.
- Assess the company's status as an emerging growth company and any associated reporting exemptions.